Ishida 2001.

Study characteristics
Methods	Study design:  Parallel‐group randomised trials Duration of trial: April 1998 to August 2000 Duration of follow‐up: Quote: ""The wounds were inspected daily until the patients were discharged from the hospital." Country of origin: Japan
Participants	Baseline characteristics Number randomised: 146 participants Number analysed: 143 participants Intervention: MBP+oAB Number of participants [n]: 72 Age [years; mean (range)]: 62 (37‐87) Gender [male/female; n]: 47/25 Control: MBP Number of participants [n]: 71 Age [years, mean (range)]: 65 (21‐89) Gender [male/female; n]: 42/29 Inclusion criteria  Quote: ""Patients with colorectal diseases, surgically treated" Exclusion criteria Quote: ""The patients in both groups were excluded if a full mechanical bowel preparation was not feasible or if they had taken any antibiotics within 14 days before surgery" Baseline imbalances none
Interventions	Comparison Intervention: MBP+oAB Control: MBP MBP Agent(s): polyethylene glycol lavage Dose per administration: 2000 mL Time(s) of intake: on the day prior to surgery (15:00–19:00 h) Route: oral Concomitant medications: ‐ oAB Agent(s): kanamycin and erythromycin Dose per administration: 500 mg and 400 mg Time(s) of intake: four doses per day for 2 days before surgery Route:oral Concomitant medications: ‐ Perioperative intravenous antibiotic prophylaxis Agent(s): cefotiam Dose per administration: 1 g Time(s) of intake: Quote: ""after the induction of anesthesia, and then again within 1 h after completing surgery. An additional four doses were given twice a day for 2 consecutive days. Patients with renal dysfunction were not given additional doses of cefotiam when appropriate." Adherence to regimen: ‐
Outcomes	Outcomes sought in review and reported in trial SSI Anastomotic leakage Outcomes sought but not reported in trial Mortality Postoperative complications (mild D/C I + II or severe D/C III+IV) Incidence of postoperative ileus Length of hospital stay Side effects of Intervention(s) Outcomes reported in trial but not used in review MRSA infection
Notes	Source of funding: ‐ Conflicts of interest: ‐ Ethics approval: ‐ Informed consent: ‐ Clinical trials registration: ‐ Sample size calculation: ‐